Pawinee Rerknimitr

Dr. Pawinee Rerknimitr

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2017 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
AOAtsushi Otsuka
Atsushi Otsuka
TNTakashi Nomura
Takashi Nomura
PRPawinee Rerknimitr
Pawinee Rerknimitr
JSJudith A. Seidel
Judith A. Seidel
THTetsuya Honda
Tetsuya Honda
KKKenji Kabashima
Kenji Kabashima

5 June 2017 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
PRPawinee Rerknimitr
Pawinee Rerknimitr
AOAtsushi Otsuka
Atsushi Otsuka
CNChisa Nakashima
Chisa Nakashima
KKKenji Kabashima
Kenji Kabashima
Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life. Extensive recent studies have shed light on the multifaceted pathogenesis of the disease. The complex interplay among skin barrier deficiency, immunological derangement, and pruritus contributes to the development, progression, and chronicity of the disease. Abnormalities in filaggrin, other stratum corneum constituents, and tight junctions induce and/or promote skin inflammation. This inflammation, in turn, can further deteriorate the barrier function by downregulating a myriad of essential barrier-maintaining molecules. Pruritus in AD, which may be due to hyperinnervation of the epidermis, increases pruritogens, and central sensitization compromises the skin integrity and promotes inflammation. There are unmet needs in the treatment of AD. Based on the detailed evidence available to date, certain disease mechanisms can be chosen as treatment targets. Numerous clinical trials of biological agents are currently being conducted and are expected to provide treatments for patients suffering from AD in the future. This review summarizes the etiopathogenesis of the disease and provides a rationale for choosing the novel targeted therapy that will be available in the future.

1 December 2017 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
TTTherdpong Tempark
Therdpong Tempark
PSPatompong Satapornpong
Patompong Satapornpong
PRPawinee Rerknimitr
Pawinee Rerknimitr
NNNontaya Nakkam
Nontaya Nakkam
NSNiwat Saksit
Niwat Saksit
CSCHONLAPHAT Sukasem
CHONLAPHAT Sukasem
Objectives A previous publication in Chinese leprosy patients showed that the HLA-B*13:01 allele is a strong genetic marker for dapsone-induced drug hypersensitivity reactions, however there are no data describing whether HLA-B*13:01 is a valid marker for prediction of dapsone-induced drug hypersensitivity reactions in other ethnicities or nonleprosy patients. The aim of this study is to investigate whether there is an association between HLA genotypes and dapsone-induced severe cutaneous adverse reactions (SCARs) in Thai nonleprosy patients. Patients and methods HLA-B genotypes of 15 patients with dapsone-induced SCARs (11 drug reaction with eosinophilia and systemic symptoms, 4 Stevens–Johnson syndrome/toxic epidermal necrolysis), 29 control patients, and 986 subjects from the general Thai population were determined by the reverse PCR sequence-specific oligonucleotides probe. Results The HLA-B*13:01 allele was significantly associated with dapsone-induced SCARs compared with dapsone-tolerant controls (odds ratio: 54.00, 95% confidence interval: 7.96–366.16, P=0.0001) and the general population (odds ratio: 26.11, 95% confidence interval: 7.27–93.75, P=0.0001). In addition, HLA-B*13:01 associated with dapsone-induced SJS-TEN (OR: 40.50, 95% confidence interval: 2.78-591.01, P=0.0070) and DRESS (OR: 60.75, 95% confidence interval: 7.44-496.18, P=0.0001). Conclusion This study demonstrated an association between HLA-B*13:01 and dapsone-induced SCARs including Stevens–Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms in nonleprosy patients. Moreover, these results suggest that the HLA-B*13:01 allele may be a useful genetic marker for prediction of dapsone-induced SCARs in Thai and Han-Chinese populations.

1 October 2016 in Allergology International
Verified
Journal Article
Open access
AHAkarin Hiransuthikul
Akarin Hiransuthikul
TRThanapoom Rattananupong
Thanapoom Rattananupong
JKJettanong Klaewsongkram
Jettanong Klaewsongkram
PRPawinee Rerknimitr
Pawinee Rerknimitr
MPMarisa Pongprutthipan
Marisa Pongprutthipan
KRKiat Ruxrungtham
Kiat Ruxrungtham
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but life-threatening adverse drug reaction. Several criteria have been established to aid the diagnosis. However, patients with DRESS remained underdiagnosis and undertreatment. Medical records of hospitalized patients at the King Chulalongkorn Memorial Hospital from January 2004-December 2014 due to DRESS were enrolled retrospectively using RegiSCAR diagnostic criteria. A total of 52 patients were included. Thirty-seven patients (71.2%) were female. The four most common causative agents were phenytoin (23.1%), nevirapine (17.3%), allopurinol (15.4%), and cotrimoxazole (13.5%). The overall prevalence was 9.63 cases per 100,000 inpatients. Median onset time (IQR) was 16 (9-27) days. Allopurinol was associated with longer onset time than others (p = 0.014). skin rash 100%, fever 78.8%, and lymphadenopathy 50%. The majority (84.6%) had single internal organ involvement. The most common internal organ involvement was liver (94.2%). Allopurinol was associated with higher incidence of renal involvement (p = 0.01). Up to 60% of patients had eosinophilia. Allopurinol was associated with higher eosinophilia (p = 0.003). A half of patients received systemic corticosteroids. Two mortality cases were reported (omeprazole-fulminant hepatitis and phenytoin-nosocomial infection). DRESS is associated with severe morbidity and mortality. Phenytoin, nevirapine, allopurinol, and cotrimoxazole were the major causes. Allopurinol-induced DRESS had the longest onset time, and was associated with higher eosinophilia and incidence of renal involvement. Raising awareness among both health care providers and public for early detection and withdrawal of the causative agent is critical to save life and reduce morbidity.

10 January 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
CSCHONLAPHAT Sukasem
CHONLAPHAT Sukasem
CCChonlawat Chaichan
Chonlawat Chaichan
TNThapanat Nakkrut
Thapanat Nakkrut
PSPatompong Satapornpong
Patompong Satapornpong
KJKanoot Jaruthamsophon
Kanoot Jaruthamsophon
WAWichai Aekplakorn
Wichai Aekplakorn
The HLA-B∗15:02 allele has been reported to have a strong association with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Thai patients. The HLA-B alleles associated with carbamazepine-induced maculopapular exanthema (MPE) and the drug reaction with eosinophilia and systemic symptoms (DRESS) among the Thai population have never been reported. The aim of the present study was to carry out an analysis of the involvement of HLA-B alleles in carbamazepine-induced cutaneous adverse drug reactions (cADRs) in the Thai population. A case-control study was performed by genotyping the HLA-B alleles of Thai carbamazepine-induced hypersensitivity reaction patients (17 MPE, 16 SJS/TEN, and 5 DRESS) and 271 carbamazepine-tolerant controls. We also recruited 470 healthy Thai candidate subjects who had not taken carbamazepine. HLA-B∗15:02 showed a significant association with carbamazepine-induced MPE (P=0.0022, odds ratio (OR) (95% confidence interval [CI]) = 7.27 (2.04–25.97)) and carbamazepine-induced SJS/TEN (P=4.46×10−13; OR (95% CI) = 70.91(19.67–255.65)) when compared with carbamazepine-tolerant controls. Carbamazepine-induced SJS/TEN also showed an association with HLA-B∗15:21 allele (P=0.013; OR (95% CI) = 9.54 (1.61–56.57)) when compared with carbamazepine-tolerant controls. HLA-B∗58:01 allele was significantly related to carbamazepine-induced MPE (P=0.007; OR (95% CI) = 4.73 (1.53–14.66)) and DRESS (P=0.0315; OR (95% CI) = 7.55 (1.20–47.58)) when compared with carbamazepine-tolerant controls. These alleles may serve as markers to predict carbamazepine-induced cADRs in the Thai population.

10 March 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
SSSupaporn Suwanchote
Supaporn Suwanchote
MRMuanpetch Rachayon
Muanpetch Rachayon
PRPongsawat Rodsaward
Pongsawat Rodsaward
JWJongkonnee Wongpiyabovorn
Jongkonnee Wongpiyabovorn
TDTawatchai Deekajorndech
Tawatchai Deekajorndech
DCDirekrit Chiewchengchol
Direkrit Chiewchengchol